| Literature DB >> 34934945 |
Ken-Ichi Oinuma1,2, Masato Suzuki3, Arata Sakiyama1, Taishi Tsubouchi1,2, Kozo Saeki4, Kanako Sato1, Mamiko Niki1,2, Koichi Yamada2,5, Keigo Shibayama6, Hiroshi Kakeya2,5, Yukihiro Kaneko1,2.
Abstract
OBJECTIVES: To characterize Acinetobacter baumannii OCU_Ac16a, a clinical isolate co-harbouring three acquired carbapenemase genes, bla NDM-1, bla TMB-1, and bla OXA-58, and assess the clinical significance of so-called multiple-carbapenemase producers.Entities:
Year: 2021 PMID: 34934945 PMCID: PMC8684466 DOI: 10.1093/jacamr/dlab191
Source DB: PubMed Journal: JAC Antimicrob Resist ISSN: 2632-1823
Characteristics of replicons identified in OCU_Ac16a
| Replicon | Size (bp) | Antimicrobial resistance genes |
| Elements related to plasmid mobility | Frequencies of plasmid transfer |
|---|---|---|---|---|---|
| Chromosome | 3 992 063 |
| – | – | – |
| pOCU_Ac16a_1 | 73 028 | ND | GR6 | MOBF family relaxase, TraD-like T4CP, MPFF | – |
| pOCU_Ac16a_2 | 41 087 |
| ND |
| 2.5 × 10−5–1.5 × 10−2 ( |
| pOCU_Ac16a_3 | 13 096 |
| GR4 | ND | ND ( |
ND, not detected; –, not applicable or not tested; GR, homology group; MOB, mobilization; T4CP, type IV coupling protein; MPF, mating pair formation; oriT, origin of transfer.
The recipient strains used are indicated in parentheses.
Results from four independent experiments.
Antimicrobial susceptibility of strains used in this study
| Strain | Antimicrobials | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PIP | CAZ | FEP | IPM | MEM | FDC | GEN | AMK | LVX | CST | MIN | TGC | |
| OCU_Ac16a | ≥256 (R) | ≥256 (R) | ≥256 (R) | ≥512 (R) | ≥512 (R) | 32 (R); 6 mm (R) | 1 (S) | 8 (S) | 1 (S) | 0.094 (S) | 0.031 (S) | 0.25 (S) |
| OCU_Ac16b | ≥256 (R) | ≥256 (R) | 48 (R) | ≥512 (R) | ≥512 (R) | NA; 21 mm (S) | 0.75 (S) | 3 (S) | 1.5 (S) | 0.094 (S) | 0.031 (S) | 0.25 (S) |
| ATCC 19606T RFP50R | 24 (I) | 4 (S) | 8 (S) | 0.5 (S) | 2 (S) | ≤0.031 (S); 28 mm (S) | 12 (I) | 16 (S) | 0.38 (S) | 0.094 (S) | NT | NT |
| ATCC 19606T RFP50R with pOCU_Ac16a_2 | ≥256 (R) | ≥256 (R) | ≥256 (R) | ≥512 (R) | ≥512 (R) | 0.5 (S); 20 mm (S) | 8 (I) | 192 (R) | 0.25 (S) | 0.094 (S) | NT | NT |
| ATCC 19606T RFP50R with pOCU_Ac16a_3 | ≥256 (R) | 4 (S) | 8 (S) | 64 (R) | 32 (R) | ≤0.031 (S); 29 mm (S) | NT | NT | NT | NT | NT | NT |
PIP, piperacillin; CAZ, ceftazidime; FEP, cefepime; IPM, imipenem; MEM, meropenem; FDC, cefiderocol; GEN, gentamicin; AMK, amikacin; LVX, levofloxacin; CST, colistin; MIN, minocycline; TGC, tigecycline; S, susceptible; I, intermediate; R, resistant; NA, not applicable; NT, not tested.
MICs (mg/L) determined by performing Etest (for PIP, CAZ, FEP, GEN, AMK, LVX, and CST) or employing the microdilution method (for IPM, MEM, FDC, MIN, and TGC). The observed diameters of the zone of inhibition from FDC disc diffusion assays are shown.